Indian drugmaker Cipla drops ahead of quarterly results

Cipla

30/10/2025 04:41

** India's no. 3 drugmaker Cipla CIPL.NS drops 1.3% to 1,561 rupees

** Drugmaker to report second-quarter results later in the day

** Analysts expect CIPL to post ~4% Y/Y climb in Q2 consol profit and 5.4% Y/Y rise in revenue - data compiled by LSEG

** Analysts expect subdued US sales for CIPL on price weakness in generic Revlimid and intense competition from smaller players

** The U.S. is CIPL's biggest market by sales

** Rival Dr Reddy's REDY.NS missed Q2 profit view last week and reported lower US sales

** CIPL rated "Buy" on avg by 35 analysts, median PT at 1,727.50 rupees - data compiled by LSEG

** YTD, CIPL up 2.5% vs 5.3% drop in pharma index .NIPHARM

(Reporting by Kashish Tandon in Bengaluru)

((Kashish.tandon@thomsonreuters.com))